JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD

Reference Data

ISIN LU2050612402
Valor Number
Bloomberg Global ID
Fund Name JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD
Fund Provider JPMorgan Asset Management (Switzerland) LLC Dreikönigstrasse 37
Postfach
8022 Zürich
Tel. +41 (0)44 206 86 00
Fund Provider JPMorgan Asset Management (Switzerland) LLC
Representative in Switzerland JPMorgan Asset Management (Switzerland) LLC
Genève
Phone: +41 22 744 11 11
Distributor(s) JP Morgan Asset Management (Europe) Sàrl
Senningerberg
Phone: +352 34 10 1
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.
Peculiarities

Fund Prices

Current Price * 94.26 USD 15.11.2024
Previous Price * 98.28 USD 14.11.2024
52 Week High * 110.81 USD 28.02.2024
52 Week Low * 90.42 USD 17.11.2023
NAV * 94.26 USD 15.11.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 517,397,475
Unit/Share Assets *** 142,194,071
Trading Information SIX

Performance

YTD Performance -7.69% 29.12.2023
15.11.2024
YTD Performance (in CHF) -2.35% 29.12.2023
15.11.2024
1 month -6.45% 15.10.2024
15.11.2024
3 months -7.32% 15.08.2024
15.11.2024
6 months -6.12% 15.05.2024
15.11.2024
1 year +4.33% 15.11.2023
15.11.2024
2 years -18.06% 15.11.2022
15.11.2024
3 years -39.94% 15.11.2021
15.11.2024
5 years -19.04% 06.03.2020
15.11.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Gilead Sciences Inc 3.76%
Alnylam Pharmaceuticals Inc 3.56%
Novartis AG Registered Shares 3.26%
Vertex Pharmaceuticals Inc 3.19%
Bio-Techne Corp 3.11%
Amgen Inc 3.02%
Arcellx Inc 2.89%
Lonza Group Ltd 2.89%
Krystal Biotech Inc 2.82%
Astellas Pharma Inc 2.81%
Last data update 31.10.2024

Cost / Risk

TER *** 0.95%
TER date *** 30.06.2024
Performance Fee ***
PTR
Max. Management Fee *** 0.72%
Ongoing Charges *** 0.93%
SRRI ***
SRRI date *** 31.10.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)